Experimental drug offers hope for tough blood cancers
NCT ID NCT07250646
Summary
This early-stage study is testing a new drug called rebecsinib in patients with two types of advanced blood cancers: secondary acute myeloid leukemia that has returned or not responded to treatment, and higher-risk myelofibrosis. The main goals are to find the safest dose and see how well patients tolerate the drug. Participants will receive the drug through infusions on specific days during 28-day treatment cycles.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UC San Diego Moores Cancer Center
San Diego, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.